OverviewSuggest Edit
Novartis is a company that researches, develops, manufactures, and markets a range of healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as contact lenses and contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers.
| Type | Public | |
| Founded | 1996 | |
| HQ | Basel, CH | Map |
| Website | novartis.com | |
| Employee Ratings | More |
Recent NewsAll News
- Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
- Global Contact Lens Market Study 2020-2025 Featuring Profiles of Major Players Essilor Int'l, Novartis, Bausch Health Companies, Zeiss Group, and the Cooper Companies Amongst Others
- AccessNow wins $250,000 USD Novartis Prize for its accessibility platform
- Novartis Pharmaceuticals Agrees To Pay $678 Million To Settle Shepherd, Finkelman, Miller & Shah, LLP False Claims Act Qui Tam Case
Key People/Management at Novartis
Vasant Narasimhan
Chief Executive Officer
Joerg Reinhardt
Chairman
Steven Baert
Chief People & Organization Officer
Enrico Vanni
Vice Chairman
Ameet Mallik
Executive Vice President, Novartis Oncology US
Bertrand Bodson
Chief Digital Officer
Novartis Office Locations
Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 167 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Basel, CH
Fabrikstrasse 18
Basel, CH
Klybeckstrasse 141
Schweizerhalle, CH
Rothausstrasse 61
Stein, CH
Schaffhauserstrasse
Novartis Financials and Metrics
Novartis Revenue
Novartis's revenue was reported to be $49.11 b in FY, 2017 which is a 1.2% increase from the previous period.
| USD | |
|---|---|
Revenue (FY, 2017) | 49.1b |
Revenue growth (FY, 2016 - FY, 2017), % | 1.2% |
Gross profit (FY, 2017) | 31.9b |
Gross profit margin (FY, 2017), % | 65% |
Net income (FY, 2017) | 7.7b |
Market capitalization (6-Jul-2020) | 191.0b |
Closing stock price (6-Jul-2020) | 83.5 |
Cash (31-Dec-2017) | 8.9b |
Novartis's current market capitalization is CHF191 b.
- Source: Company Filings
| USD | FY, 2016 | FY, 2017 |
|---|---|---|
Cash | 7.0b | 8.9b |
Accounts Receivable | 8.2b | 8.6b |
Inventories | 6.3b | 6.9b |
Current Assets | 24.9b | 28.2b |
- Source: Company Filings
| USD | FY, 2015 | FY, 2016 | FY, 2017 |
|---|---|---|---|
Net Income | 7.0b | 6.7b | 7.7b |
Cash From Operating Activities | 11.9b | 11.5b | 12.6b |
Purchases of PP&E | (2.4b) | (1.9b) | (1.7b) |
Cash From Investing Activities | (10.8b) | (3.4b) | (3.1b) |
- Source: Company Filings
Novartis Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| Amblyotech | April 21, 2020 | |
| The Medicines Company | November 25, 2019 | $9.70 b |
| Endocyte | October 18, 2018 | |
| Advanced Accelerator Applications | October 30, 2017 | $3.90 b |
| AveXis | $8.70 b |
Novartis Cybersecurity Score
Novartis Revenue Breakdown
Novartis revenue breakdown by business segment: 67.2% from Innovative Medicines, 20.5% from Sandoz and 12.3% from Alcon
Novartis revenue breakdown by geographic segment: 34.5% from United States, 7.5% from Germany, 5.1% from France, 6.5% from Japan and 46.5% from Other
Novartis Online and Social Media Presence
269.76k Twitter followers
Novartis has 269.76k Twitter Followers. The number of followers has increased 0.2% month over month and increased 1% quarter over quarter
Novartis's Trends
Twitter Engagement Stats for @novartis
12.3k
Tweets
575
Following
269.8k
Followers
27
Tweets last 30 days
2.8
Avg. likes per Tweet
33.3%
Tweets with engagement
Novartis News and Updates
July 07, 2020
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
Basel, July 7, 2020 — Novartis today announced that the European Commission (EC) has approved Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a mainte…
July 06, 2020
Global Contact Lens Market Study 2020-2025 Featuring Profiles of Major Players Essilor Int'l, Novartis, Bausch Health Companies, Zeiss Group, and the Cooper Companies Amongst Others
DUBLIN, July 6, 2020 /PRNewswire/ -- The "Contact Lens Market- Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The global contact lens market is projected to register a CAGR of 5.92% during the forecast period, 2020 to 2025. In order...
July 02, 2020
AccessNow wins $250,000 USD Novartis Prize for its accessibility platform
Toronto-based AccessNow recently won the Novartis Prize for Assistive Tech for Multiple Sclerosis (MS) beating over 150 submissions. AccessNow plans to use the funding...
July 02, 2020
Novartis Pharmaceuticals Agrees To Pay $678 Million To Settle Shepherd, Finkelman, Miller & Shah, LLP False Claims Act Qui Tam Case
NEW YORK, July 1, 2020 /PRNewswire/ -- James E. Miller of Shepherd, Finkelman, Miller & Shah, LLP ("SFMS")(www.sfmslaw.com), Lead Counsel for Plaintiff-Relator, Oswald Bilotta (the "Relator" or "Whistleblower"), announced today that Novartis Pharmaceuticals Corporation ("Novartis") has...
July 01, 2020
Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US and positioning company for the future by fully scaling its next-generation digital engagement technologies
Basel, July 2, 2020 – Novartis has finalized its previously disclosed agreement with the US Attorney’s Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conduc…
June 30, 2020
The CEO of Novartis on Developing Drugs During a Pandemic
Vas Narasimhan talks about drug prices, vaccine development, the rise and fall of hydroxychloroquine, and how Big Pharma might win back the trust of consumers.
Novartis Frequently Asked Questions
When was Novartis founded?
Novartis was founded in 1996.
Who are Novartis key executives?
Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Steven Baert.
How many employees does Novartis have?
Novartis has 103,914 employees.
What is Novartis revenue?
Latest Novartis annual revenue is $49.1 b.
What is Novartis revenue per employee?
Latest Novartis revenue per employee is $472.6 k.
Who are Novartis competitors?
Competitors of Novartis include Bayer, Pfizer and Johnson & Johnson.
Where is Novartis headquarters?
Novartis headquarters is located at Fabrikstrasse 2, Basel.
Where are Novartis offices?
Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 167 other locations.
How many offices does Novartis have?
Novartis has 185 offices.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies